Monthly Archives: June 2021

Why is the FDA approving extremely risky Alzheimer’s therapies?

Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision By Andrew Joseph STAT A third member of a Food and Drug Administration expert panel has resigned over the agency’s contentious approval of an Alzheimer’s therapy this week, a sign … Continue reading

Posted in Uncategorized | Comments Off on Why is the FDA approving extremely risky Alzheimer’s therapies?